Bioventus (BVS) Cash & Equivalents (2020 - 2026)

Bioventus (BVS) has 7 years of Cash & Equivalents data on file, last reported at $35.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 57.21% year-over-year to $35.8 million; the trailing twelve-month figure through Mar 2026 stood at $35.8 million (up 57.21% YoY), and the FY2025 full-year result was $51.2 million, up 23.22% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $35.8 million, down from $51.2 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $51.2 million in Q4 2025 and bottomed at $22.8 million in Q1 2025.
• The 5-year median for Cash & Equivalents is $34.4 million (2022), against an average of $35.3 million.
• The widest annual swing landed in 2022, when Cash & Equivalents slumped 78.85%; it then jumped 72.07% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $30.2 million in 2022, then grew by 22.45% to $37.0 million in 2023, then climbed by 12.49% to $41.6 million in 2024, then grew by 23.22% to $51.2 million in 2025, then slumped by 30.04% to $35.8 million in 2026.
• The last three Cash & Equivalents figures came in at $35.8 million (Q1 2026), $51.2 million (Q4 2025), and $42.2 million (Q3 2025), per Business Quant data.

Peer Comparison